Pluristem to Present at LD MICRO Conference April 29, 2008

NEW YORK--(BUSINESS WIRE)--Apr 28, 2008 - Pluristem Therapeutics
Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated
to the commercialization of non-personalized (allogeneic) cell
therapy products for a variety of degenerative, ischemic and
autoimmune indications, announced today that the Company will
present at the LD Micro Conference on Tuesday, April 29th at 5:00
PM PDT. Senior Vice President Corporate Development, William
Prather RPh, MD, will represent the Company. The conference will be
held at the Omni Los Angeles Hotel in Los Angeles, California.

LD MICRO is a by-invitation only newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published an annual list of recommended stocks as well
as comprehensive reports on selected names throughout the year.

Mr. Zami Aberman, Pluristem's President & CEO, stated: "We
are pleased that LD MICRO has invited us to this prestigious
conference, which allows us to present Pluristem's unique and
innovative cellular therapeutics business model to the investment
community. Pluristem has recently announced pre-clinical data that
shows potential of our PLX (Placental eXpanded) cells to be
therapeutically beneficial to millions of Stroke and MS patients,
in addition to those suffering from Peripheral Artery Disease or in
need of Bone Marrow Transplantation. This data represents the
ability of these cells to become a most promising product of the
21st century."

For information on the list of presenting companies or to
register for the event, please visit http://ldmicro.com or call
310-862-4512.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company
dedicated to the commercialization of non-personalized (allogeneic)
cell therapy products for the treatment of several severe
degenerative, ischemic and autoimmune disorders. The Company is
developing a pipeline of products, stored ready-to-use, that are
derived from the human placenta, a non-controversial,
non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells (MSCs) are expanded in
the Company's proprietary PluriX(TM) 3D bioreactor, which imitates
the natural microstructure of bone marrow and does not require
supplemental growth factors or other exogenous materials. Pluristem
believes the resultant PLX (PLacental eXpanded) cells are
multi-potent and able to differentiate into a variety of cell
types. Recent evidence also suggests their efficacy may be related
to the secretion of cytokines or other potent immune modulators.
Furthermore, PLX cells are immune privileged and have
immunomodulatory properties, thus protecting the recipient from
immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended
to improve the quality of life of millions of people suffering from
peripheral artery disease (PAD). The Company's products in
development also include the PLX-I, targeting the global shortfall
of matched tissue for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem cells (HSCs)
contained in umbilical cord blood; the PLX-STROKE, targeting
ischemic stroke victims; and the PLX-MS, targeting Multiple
Sclerosis.

Pluristem has offices in the USA with research and manufacturing
facilities in Israel.

This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or
current expectations. For example, when we say that our recently
announced pre-clinical data shows potential of our PLX (Placental
eXpanded) cells to be therapeutically beneficial to millions of
Stroke and MS patients, in addition to those suffering from
Peripheral Artery Disease or in need of Bone Marrow
Transplantation; that this data represents the ability of these
cells to become a most promising product of the 21st century; we
are using forward-looking statements. Factors that could prevent
our forward looking statements from being achieved include that we
may be unable to get regulatory approval for our products; we may
be unsuccessful in developing any products; our technology may not
be validated as we progress further and our methods may not be
accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties may
develop with our process; results in the laboratory may not
translate to equally good results in real surgical settings; our
patents may not be sufficient to protect essential aspects of our
technology; competitors may invent better technology; our products
may not work as well as hoped or worse, our products may harm
recipients; and we may not be able to raise funds for development
or working capital when we require it. As well, our products may
never develop into useful products and even if they do, they may
not be approved for sale to the public. For further risk factors
see the Company's latest 10-KSB filed with the SEC.

For more information visit our website at www.pluristem.com, the
content of which is not part of this press release.